BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Obecure Initiates Phase II Weight Gain Prevention Study for Patients Taking Zyprexa


3/13/2007 1:24:37 PM

RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure has conducted the first initiation visit for its Phase II clinical trial to evaluate the efficacy of the company’s OBE101 drug candidate for prevention of weight gain in patients treated with Zyprexa, (olanzapine) an antipsychotic medication. The study is a double-blinded, placebo-controlled multicenter trial in about 78 subjects over a period of four months. The study, approved by Health Canada and the central IRB, will be conducted at several psychiatric medical centers across Canada and will start at Penticton, BC. The trial is being conducted with the partial financial support of Eli Lilly & Co., the manufacturer of Zyprexa.

Read at BioSpace.com

Obecure
 
 
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES